Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Ofatumumab Dose-finding in RRMS Patients
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Study hints of rituximab MS benefit
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Role of the Blood-Brain Barrier in Multiple Sclerosis.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Pages